|
1
|
Gabazza EC, Taguchi O, Yamakami T,
Machishi M, Ibata H and Suzuki S: Evaluating prethrombotic state in
lung cancer using molecular markers. Chest. 103:196–200. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Masago K, Fujita S, Mio T, Togashi Y, Kim
YH, Hatachi Y, Fukuhara A, Irisa K, Sakamori Y and Mishima M:
Clinical significance of the ratio between the alpha 2 plasmin
inhibitor-plasmin complex and the thrombin-antithrombin complex in
advanced non-small cell lung cancer. Med Oncol. 28:351–356. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tas F, Kilic L, Serilmez M, Keskin S, Sen
F and Duranyildiz D: Clinical and prognostic significance of
coagulation assays in lung cancer. Respir Med. 107:451–457. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Terraube V, O'Donnell JS and Jenkins PV:
Factor VIII and von Willebrand factor interaction: Biological,
clinical and therapeutic importance. Haemophilia. 16:3–13. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sporn LA, Marder VJ and Wagner DD:
Inducible secretion of large, biologically potent von Willebrand
factor multimers. Cell. 46:185–190. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sadler JE: Biochemistry and genetics of
von Willebrand factor. Annu Rev Biochem. 67:395–424. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujikawa K, Suzuki H, McMullen B and Chung
D: Purification of human von Willebrand factor-cleaving protease
and its identification as a new member of the metalloproteinase
family. Blood. 98:1662–1666. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moake JL: Thrombotic microangiopathies. N
Engl J Med. 347:589–600. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Franchini M, Favaloro EJ, Targher G and
Lippi G: ABO blood group, hypercoagulability, and cardiovascular
and cancer risk. Crit Rev Clin Lab Sci. 49:137–149. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jenkins PV and O'Donnell JS: ABO blood
group determines plasma von Willebrand factor levels: A biologic
function after all? Transfusion. 46:1836–1844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sousa NC, Anicchino-Bizzacchi JM,
Locatelli MF, Castro V and Barjas-Castro ML: The relationship
between ABO groups and subgroups, factor VIII and von Willebrand
factor. Haematologica. 92:236–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Terraube V, Marx I and Denis CV: Role of
von Willebrand factor in tumor metastasis. Thromb Res. 120:(Suppl
2). S64–S70. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Martini F, Ferroni P, Guadagni F, Basili
S, Spila A, D'Alessandro R, Mineo D, Laudisi A, Portarena I,
Mariotti S, et al: Plasma von Willebrand factor antigen levels in
non-small cell lung cancer patients. Anticancer Res. 25:403–407.
2005.PubMed/NCBI
|
|
14
|
Brambilla E, Travis WD, Colby TV, Corrin B
and Shimosato Y: The new World Health Organization classification
of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Detterbeck FC, Boffa DJ and Tanoue LT: The
new lung cancer staging system. Chest. 136:260–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bais R and Philcox M: Approved
recommendation on IFCC methods for the measurement of catalytic
concentration of enzymes. Part 8. IFCC method for lactate
dehydrogenase (l-lactate: NAD+oxidoreductase, EC 1.1.1.27).
International Federation of Clinical Chemistry (IFCC). Eur J Clin
Chem Clin Biochem. 32:639–655. 1994.PubMed/NCBI
|
|
17
|
Okuno T and Selenko V: Plasma fibrinogen
determination by automated thrombin time. Am J Med Technol.
38:196–201. 1972.PubMed/NCBI
|
|
18
|
Elf JL, Strandberg K and Svensson PJ:
Performance of two relatively new quantitative D-dimer assays
(Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep
vein thrombosis. Thromb Res. 124:701–705. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barrowcliffe TW, Raut S, Sands D and
Hubbard AR: Coagulation and chromogenic assays of factor VIII
activity: General aspects, standardization, and recommendations.
Semin Thromb Hemost. 28:247–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goad KE and Gralnick HR: Coagulation
disorders in cancer. Hematol Oncol Clin North Am. 10:457–484. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guadagni F, Ferroni P, Basili S, Facciolo
F, Carlini S, Crecco M, Martini F, Spila A, D'Alessandro R, Aloe S,
et al: Correlation between tumor necrosis factor-alpha and D-dimer
levels in non-small cell lung cancer patients. Lung Cancer.
44:303–310. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oleksowicz L, Bhagwati N and
DeLeon-Fernandez M: Deficient activity of von Willebrand's
factor-cleaving protease in patients with disseminated
malignancies. Cancer Res. 59:2244–2250. 1999.PubMed/NCBI
|
|
23
|
Unsal E, Atalay F, Atikcan S and Yilmaz A:
Prognostic significance of hemostatic parameters in patients with
lung cancer. Respir Med. 98:93–98. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sugimoto Y, Watanabe M, Oh-Hara T, Sato S,
Isoe T and Tsuruo T: Suppression of experimental lung colonization
of a metastatic variant of murine colon adenocarcinoma 26 by a
monoclonal antibody 8F11 inhibiting tumor cell-induced platelet
aggregation. Cancer Res. 51:921–925. 1991.PubMed/NCBI
|
|
25
|
Oleksowicz L, Bhagwati N, Fernandez MD,
Seno R and Etkind P: Prognostic significance of platelet
immunorelated GPIb expression in breast cancer. Cancer J Sci Am.
4:247–253. 1998.PubMed/NCBI
|
|
26
|
León-Atance P, Moreno-Mata N,
González-Aragoneses F, Cañizares-Carretero MÁ, Poblet-Martínez E,
Genovés-Crespo M, García-Jiménez MD, Honguero-Martínez AF, Rombolá
CA, Simón-Adiego CM, et al: Prognostic influence of loss of blood
group A antigen expression in pathologic stage I non-small-cell
lung cancer. Arch Bronconeumol. 48:49–54. 2012.(In English,
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Joh HK, Cho E and Choueiri TK: ABO blood
group and risk of renal cell cancer. Cancer Epidemiol. 36:528–532.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oguz A, Unal D, Tasdemir A, Karahan S,
Aykas F, Mutlu H, Cihan YB and Kanbay M: Lack of any association
between blood groups and lung cancer, independent of histology.
Asian Pac J Cancer Prev. 14:453–456. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Urun Y, Utkan G, Cangir AK, Oksuzoglu OB,
Ozdemir N, Oztuna DG, Kocaman G, Coşkun HŞ, Kaplan MA, Yuksel C, et
al: Association of ABO blood group and risk of lung cancer in a
multicenter study in Turkey. Asian Pac J Cancer Prev. 14:2801–2803.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Amundadottir L, Kraft P,
Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA,
Bueno-de-Mesquita HB, Gross M, Helzlsouer K, Jacobs EJ, et al:
Genome-wide association study identifies variants in the ABO locus
associated with susceptibility to pancreatic cancer. Nat Genet.
41:986–990. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Suadicani P, Hein HO and Gyntelberg F: ABO
phenotypes and inflammation-related predictors of lung cancer
mortality: The Copenhagen Male Study-a 16-year follow-up. Eur
Respir J. 30:13–20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klarmann D, Eggert C, Geisen C, Becker S,
Seifried E, Klingebiel T and Kreuz W: Association of ABO(H) and I
blood group system development with von Willebrand factor and
factor VIII plasma levels in children and adolescents. Transfusion.
50:1571–1580. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bowen DJ: An influence of ABO blood group
on the rate of proteolysis of von Willebrand factor by ADAMTS13. J
Thromb Haemost. 1:33–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wagner DD, Mayadas T and Marder VJ:
Initial glycosylation and acidic pH in the Golgi apparatus are
required for multimerization of von Willebrand factor. J Cell Biol.
102:1320–1324. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Choi Q, Kim JE, Kim SY, Han KS and Kim HK:
Influence of ABO type on global coagulation assay results: Effect
of coagulation factor VIII. Clin Chem Lab Med. 53:1425–1432. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mannucci PM, Capoferri C and Canciani MT:
Plasma levels of von Willebrand factor regulate ADAMTS-13, its
major cleaving protease. Br J Haematol. 126:213–218. 2004.
View Article : Google Scholar : PubMed/NCBI
|
